Identification of Novel Biomarker for Early Detection of Diabetic Nephropathy.
Kyeong-Seok KimJin-Sol LeeJae-Hyeon ParkEun Young LeeJong-Seok MoonSang-Kyu LeeJong-Sil LeeJung-Hwan KimHyung-Sik KimPublished in: Biomedicines (2021)
Diabetic nephropathy (DN) is one of the most common complications of diabetes mellitus. After development of DN, patients will progress to end-stage renal disease, which is associated with high morbidity and mortality. Here, we developed early-stage diagnostic biomarkers to detect DN as a strategy for DN intervention. For the DN model, Zucker diabetic fatty rats were used for DN phenotyping. The results revealed that DN rats showed significantly increased blood glucose, blood urea nitrogen (BUN), and serum creatinine levels, accompanied by severe kidney injury, fibrosis and microstructural changes. In addition, DN rats showed significantly increased urinary excretion of kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL). Transcriptome analysis revealed that new DN biomarkers, such as complementary component 4b (C4b), complementary factor D (CFD), C-X-C motif chemokine receptor 6 (CXCR6), and leukemia inhibitory factor (LIF) were identified. Furthermore, they were found in the urine of patients with DN. Since these biomarkers were detected in the urine and kidney of DN rats and urine of diabetic patients, the selected markers could be used as early diagnosis biomarkers for chronic diabetic nephropathy.
Keyphrases
- diabetic nephropathy
- end stage renal disease
- chronic kidney disease
- early stage
- peritoneal dialysis
- blood glucose
- type diabetes
- randomized controlled trial
- ejection fraction
- metabolic syndrome
- newly diagnosed
- multiple sclerosis
- acute myeloid leukemia
- single cell
- early onset
- neoadjuvant chemotherapy
- insulin resistance
- binding protein
- rectal cancer
- uric acid
- lymph node
- skeletal muscle
- adipose tissue
- locally advanced